Literature DB >> 6273857

Classification of multiple morphine and enkephalin binding sites in the central nervous system.

B L Wolozin, G W Pasternak.   

Abstract

Detailed competitive displacement curves of 3H-labeled [D-Ala2,Met5]enkephalinamide, [D-Ala2,D-Leu5]enkephalin, and dihydromorphine by a series of opiates and enkephalins are biphasic, suggesting multiple sites. After treatment of tissue with naloxazone, the displacement of the three 3H-labeled ligands by all opiates and enkephalins tested becomes monophasic, losing the high-affinity displacement seen with low concentrations of both opiates and enkephalins. Coupled with Scatchard analysis of saturation experiments, these findings suggest a common site that binds both opiates and enkephalins equally well and with highest affinity (Kd values, less than 1 nM). Termed the mu 1 site, it corresponds to the previously described high-affinity site and appears to be the site responsible for analgesia under normal circumstances. The low-affinity binding of [3H]dihydromorphine (Kd, 3 nM) remaining after naloxazone treatment differs dramatically from low-affinity [D-Ala2,D-Leu5]-[3H]enkephalin binding (Kd, 5 nM). The mu 2 site, corresponding to the low-affinity [3H]dihydromorphine receptor sites, binds morphine (Ki, 10 nM) and dihydromorphine (Kd, 3 nM) far better than [D-Ala2,D-Leu5]enkephalin (Ki, 50 nM). Low-affinity [D-Ala2,D-Leu5]-[3H]enkephalin receptor sites bind [D-Ala2,D-Leu5]enkephalin (Ki, 5-8 nM) more potently than morphine (Ki, 71 nM) and correspond to the previously established delta receptor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6273857      PMCID: PMC349002          DOI: 10.1073/pnas.78.10.6181

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  An endogenous morphine-like factor in mammalian brain.

Authors:  G W Pasternak; R Goodman; S H Snyder
Journal:  Life Sci       Date:  1975-06-15       Impact factor: 5.037

2.  A peptide-like substance from pituitary that acts like morphine. I. Isolation.

Authors:  H Teschemacher; K E Opheim; B M Cox; A Goldstein
Journal:  Life Sci       Date:  1975-06-15       Impact factor: 5.037

3.  Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine.

Authors:  J Hughes
Journal:  Brain Res       Date:  1975-05-02       Impact factor: 3.252

4.  Multiple opiate receptors. Enkephalins and morphine bind to receptors of different specificity.

Authors:  K J Chang; P Cuatrecasas
Journal:  J Biol Chem       Date:  1979-04-25       Impact factor: 5.157

5.  Ontogeny of opioid pharmacology and receptors: high and low affinity site differences.

Authors:  A Z Zhang; G W Pasternak
Journal:  Eur J Pharmacol       Date:  1981-07-17       Impact factor: 4.432

6.  Differential effects of protein-modifying reagents on receptor binding of opiate agonists and antagonists.

Authors:  G W Pasternak; H A Wilson; S H Snyder
Journal:  Mol Pharmacol       Date:  1975-05       Impact factor: 4.436

7.  Opiate receptor binding: effects of enzymatic treatments.

Authors:  G W Pasternak; S H Snyder
Journal:  Mol Pharmacol       Date:  1974-03       Impact factor: 4.436

8.  Identification of two related pentapeptides from the brain with potent opiate agonist activity.

Authors:  J Hughes; T W Smith; H W Kosterlitz; L A Fothergill; B A Morgan; H R Morris
Journal:  Nature       Date:  1975-12-18       Impact factor: 49.962

9.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

10.  Morphine-like peptides in mammalian brain: isolation, structure elucidation, and interactions with the opiate receptor.

Authors:  R Simantov; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

View more
  63 in total

1.  Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene.

Authors:  Y X Pan; J Xu; L Mahurter; E Bolan; M Xu; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Endomorphin analogues containing D-Pro2 discriminate different mu-opioid receptor mediated antinociception in mice.

Authors:  Shinobu Sakurada; Hiroyuki Watanabe; Takafumi Hayashi; Masayuki Yuhki; Tsutomu Fujimura; Kimie Murayama; Chikai Sakurada; Tsukasa Sakurada
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants.

Authors:  Susruta Majumdar; Joan Subrath; Valerie Le Rouzic; Lisa Polikar; Maxim Burgman; Kuni Nagakura; Julie Ocampo; Nathan Haselton; Anna R Pasternak; Steven Grinnell; Ying-Xian Pan; Gavril W Pasternak
Journal:  J Med Chem       Date:  2012-07-16       Impact factor: 7.446

4.  Splice variation of the mu-opioid receptor and its effect on the action of opioids.

Authors:  Sophy K Gretton; Joanne Droney
Journal:  Br J Pain       Date:  2014-11

Review 5.  Advances in opioid pharmacology.

Authors:  Geoffrey K Gourlay
Journal:  Support Care Cancer       Date:  2004-12-21       Impact factor: 3.603

6.  Effect of the blockade of mu1-opioid and 5HT2A-serotonergic/alpha1-noradrenergic receptors on sweet-substance-induced analgesia.

Authors:  E C C Rebouças; E N Segato; R Kishi; R L Freitas; M Savoldi; S Morato; N C Coimbra
Journal:  Psychopharmacology (Berl)       Date:  2004-12-10       Impact factor: 4.530

7.  Stabilization of the μ-opioid receptor by truncated single transmembrane splice variants through a chaperone-like action.

Authors:  Jin Xu; Ming Xu; Taylor Brown; Grace C Rossi; Yasmin L Hurd; Charles E Inturrisi; Gavril W Pasternak; Ying-Xian Pan
Journal:  J Biol Chem       Date:  2013-06-11       Impact factor: 5.157

Review 8.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

9.  Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene.

Authors:  Jin Xu; Mingming Xu; Yasmin L Hurd; Gavril W Pasternak; Ying-Xian Pan
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

Review 10.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.